Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate

NCT05404139 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT05404139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05404139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Recruiting
Start date
May 24, 2023
Completion date
February 28, 2031
Enrollment
352 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer